Provided by Tiger Fintech (Singapore) Pte. Ltd.

Arrowhead Pharmaceuticals

14.84
+0.80005.70%
Volume:563.28K
Turnover:8.28M
Market Cap:2.04B
PE:-2.88
High:14.96
Open:14.23
Low:14.22
Close:14.04
Loading ...

Arrowhead Pharmaceuticals Announces Acceptance of New Drug Application by U.S. FDA of Plozasiran for the Treatment of Familial Chylomicronemia Syndrome

THOMSON REUTERS
·
18 Jan

Arrowhead Pharmaceuticals Inc - FDA Sets Pdufa Date for Plozasiran as November 18, 2025

THOMSON REUTERS
·
18 Jan

Arrowhead Pharmaceuticals: Strong Growth Potential Backed by siRNA Therapeutics and Financial Stability

TIPRANKS
·
03 Jan

Arrowhead Pharmaceuticals Doses First Patients in Trial of Potential Obesity Drug

MT Newswires Live
·
23 Dec 2024

Arrowhead doses 1st patients in study of ARO-INHBE for obesity treatment

TIPRANKS
·
23 Dec 2024

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of Aro-Inhbe for the Treatment of Obesity

THOMSON REUTERS
·
23 Dec 2024

Arrowhead Pharmaceuticals Price Target Maintained With a $80.00/Share by HC Wainwright & Co.

Dow Jones
·
21 Dec 2024

Arrowhead Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
20 Dec 2024

B. Riley Lowers Price Target on Arrowhead Pharmaceuticals to $51 From $55, Keeps Buy Rating

MT Newswires Live
·
12 Dec 2024

Arrowhead Pharmaceuticals: Positioned for Growth with Strategic Partnerships and siRNA Advancements

TIPRANKS
·
12 Dec 2024

Arrowhead Pharmaceuticals Is Maintained at Buy by Chardan Capital

Dow Jones
·
12 Dec 2024

Promising Clinical Trial Results Boost Confidence in Arrowhead Pharmaceuticals, Justifying Buy Rating

TIPRANKS
·
12 Dec 2024

Arrowhead announces interim results from ARO-CFB study

TIPRANKS
·
11 Dec 2024

Shareholders in Arrowhead Pharmaceuticals (NASDAQ:ARWR) have lost 66%, as stock drops 9.3% this past week

Simply Wall St.
·
07 Dec 2024

Analysts Offer Insights on Healthcare Companies: Biohaven Ltd. (BHVN), Arrowhead Pharmaceuticals (ARWR) and Heron Therapeutics (HRTX)

TIPRANKS
·
06 Dec 2024

HC Wainwright Raises Price Target on Arrowhead Pharmaceuticals to $80 From $60, Keeps Buy Rating

MT Newswires Live
·
04 Dec 2024

Arrowhead price target raised to $80 from $60 at H.C. Wainwright

TIPRANKS
·
04 Dec 2024

Arrowhead Pharmaceuticals Files Request to Initiate Phase 1/2a Trial of Obesity Treatment

MT Newswires Live
·
03 Dec 2024

Arrowhead requests regulatory clearance to initiate ARO-ALK7 trial

TIPRANKS
·
03 Dec 2024

BRIEF-Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity

Reuters
·
03 Dec 2024